Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for treatment of RA. We compared tofacitinib modified-release (MR) 11 mg once daily (QD) with tofacitinib immediate-release (IR) 5 mg twice daily (BID) in Japanese patients with RA and inadequate response to MTX. METHODS: Phase III, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Sugiyama, Naonobu, Toyoizumi, Shigeyuki, Lukic, Tatjana, Lamba, Manisha, Zhang, Richard, Chen, Connie, Stock, Thomas, Valdez, Hernan, Mojcik, Christopher, Fan, Haiyun, Deng, Chenhui, Yuasa, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293484/
https://www.ncbi.nlm.nih.gov/pubmed/30137547
http://dx.doi.org/10.1093/rheumatology/key250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293484/
https://www.ncbi.nlm.nih.gov/pubmed/30137547
http://dx.doi.org/10.1093/rheumatology/key250

Ejemplares similares